Additive Effect of Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination As Adjunctive Therapy to Travoprost

Trial Profile

Additive Effect of Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination As Adjunctive Therapy to Travoprost

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 May 2016

At a glance

  • Drugs Brimonidine/brinzolamide (Primary) ; Travoprost
  • Indications Ocular hypertension; Open-angle glaucoma
  • Focus Therapeutic Use
  • Sponsors Alcon
  • Most Recent Events

    • 28 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 24 Jan 2014 According to ClinicalTrials.gov record, planned end date changed from 1 Oct 2014 to 1 Mar 2014.
    • 24 Jan 2014 According to ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top